

SUPPLEMENT TO THE SECURITIES OFFERINGS DOCUMENT

**PART III OF THE PROSPECTUS FOR THE PUBLIC OFFERING OF THE SHARES OF
TCHAIKAPHARMA HIGH QUALITY MEDICINES INC**

The Supplement to this Securities Offerings Document is drawn up pursuant to Art. 85, Para. 2 of the POSA and in compliance with Commission Delegated Regulation (EU) № 382/2014 from the 7th of March 2014 supplementing Directive 2003/71 / EC of the European Parliament and the Council in respect to the regulatory technical standards for publishing a Supplement to the Prospectus and it only contains information relating to the occurrence of a significant new factor in the information contained in the approved Prospectus for the public offering of shares from the capital increase of Tchaikapharma High-Quality Medicines Inc., which may affect the assessment of the securities offered.

The ensuing new circumstance is the increase of the amount of the capital of Tchaikapharma High Quality Medicines Inc. by its own means through the capitalization of profits pursuant to Art. 192 in conjunction with Art. 197 of the Trade Act, as well as a change in the Company Regulations. The changes were made pursuant to the Resolution of the General Meeting of shareholders on the 20th of April 2015. It is in the interest of investors before making an investment decision to familiarize themselves with the full text of the Prospectus comprising the Registration Document, the Securities Offering Document and the Summary and with the Supplement to the Prospectus consisting of a Supplement to the Registration Document, the Supplement to the Securities Offerings Document and a Supplement to the Summary. The Prospectus contains the entire information which, according to the peculiarities of the company and the publicly offered securities, is required to make an investment decision, including the main risks related to the company and its activities. The Financial Supervision Commission has confirmed the Supplement to the Securities Offerings Document (as part of the Prospectus) with Resolution № 304 - ПД from the 21st of April 2015 and the Supplement to the Securities Offerings Document (as part of the Supplement to the Prospectus) with Resolution №/....., which is not a recommendation to invest in the offered securities. The Financial Supervision Commission is not responsible for the correctness and completeness of the information contained therein. The members of the Board of Directors of Tchaikapharma High Quality Medicines Inc. are jointly liable for the damages caused by false, misleading or incomplete data in the Supplement to the Securities Offerings Document. The legal representative of the issuer declares that, having taken all reasonable care, he is satisfied that such is the case, that the information contained in the Supplement to the Securities Offerings Document, to his best knowledge, is complete and correct, that it corresponds to the facts and contains no omission that is likely to affect its meaning and that the Supplement to the Securities Offerings Document complies with the requirements of the law. The draftsmen of the financial statements of the Company are jointly liable along with the persons referred to in the first sentence of Art. 81, Para. 3 of the POSA, for damages caused by false, misleading or incomplete data in the financial statements of the Company and the auditors - for damages caused by their audited financial statements.

The 30th of April 2015

TCHAIKAPHARMA HIGH QUALITY MEDICINES INC

Investors can obtain the Prospectus and the Supplement to the Prospectus to get acquainted with its contents in the office of Tchaikapharma High Quality Medicines Inc. at:

1172 Sofia, № 1GM Dimitrov Blvd., every working day from 08:30 to 17.30 o'clock
as well as at the Information Center of the Financial Supervision Commission at:

Sofia, № 16 Budapest Str., every working day from 9.00 to 17.00 o'clock.
PBX of the Commission: 02/94 04 999.

The telephone number of Tchaikapharma High Quality Medicines Inc. is: 02/9603 634, contact person: Biser Ivanov.

Tchaikapharma High Quality Medicines Inc. informs its potential investors that investing in the offered shares involves certain risks, which are discussed in detail in the Registration document, insofar as it contains information on the risks associated with the Issuer and his activities. Risks related to the securities offered are detailed in the Securities Offerings Document.

1. THE SUPPLEMENT TO THE SECURITIES OFFERING DOCUMENT IS TO UPDATE SECTION:

IV. INFORMATION ON THE SECURITIES TO BE OFFERED / ADMITTED TO TRADING,

1. Type and class of the shares offered

THE CONTENT OF THE SECTION WILL APPEAR AS FOLLOWS:

49,600,000 ordinary registered shares will be registered for trade on the Bulgarian Stock Exchange and will be subject to a secondary public offering on the Stock Exchange.

The ISIN code of the issue is BG 1100008074.

All issued by the Company shares are with a nominal value of BGN 1 (one) each and are of the same class. The shares give equal rights to the shareholders, namely:

1. Voting right
2. The right to a dividend and liquidation share in proportion to the nominal value
3. The right of every shareholder in a capital increase to acquire shares corresponding to his/her share in the capital before the increase
4. The right of each shareholder to participate in the management of the company, to elect and be elected in the management bodies
5. The right to information, including the right to get acquainted with the materials on the announced agenda of the General Meeting of the shareholders (GMS) and to obtain them on demand
6. The right to seek judicial revision of the decisions of the General Meeting of the shareholders when they do not comply with the law and the regulations

2. THE SUPPLEMENT TO THE SECURITIES OFFERING DOCUMENT IS TO UPDATE SECTION:

IV. INFORMATION ON THE SECURITIES TO BE OFFERED / ADMITTED TO TRADING,

6. Resolutions and approvals by virtue of which have been created or will be created and / or issued securities

THE CONTENT OF THE SECTION WILL APPEAR AS FOLLOWS:

The Company was founded and registered in the Commercial Register as a joint stock company with a Resolution from the 14th of March 2000 under company № 1096/2000 of the Varna District Court, with a capital of BGN 500 000, divided into 500 ordinary registered shares with voting rights, with a nominal value of BGN 1000 each.

Pursuant to the resolution of the General Meeting, listed as Resolution № 7118 of 26th of October 2005, under company case № 1096/2000 of the Varna District Court, the nominal value per share was reduced and become one BGN and the capital was increased from BGN 500 000 to BGN 2 500 000, through the issuance of 2 000 000 ordinary registered shares with voting rights, with a nominal

TCHAIKAPHARMA HIGH QUALITY MEDICINES INC

value of BGN 1 each. The capital increase was carried out by capitalization of profits pursuant to Art. 197 of the Commercial Code.

Pursuant to the resolution of the General Meeting from the 19th of April 2006, listed as Resolution № 3168 from the 04th of May 2006, under company case № 1096/2000 of the Varna District Court, the capital was increased from BGN 2 500 000 to BGN 5 299 000, by issuing 2 799 000 new ordinary registered shares with voting rights, with a nominal value of BGN 1 each. The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.

Pursuant to the resolution of the General Meeting from the 15th of October of 2006 a change was made to the type of shares where all shares of the Company were dematerialized.

Pursuant to the resolution of the General Meeting from the 7th of April 2007 the capital was increased from BGN 5 299 000 to BGN 10 598 000, by issuing 5 299 000 new ordinary shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.

Pursuant to the resolution of the General Meeting from the 17th of February 2008 the capital was increased from BGN 10 598 000 to BGN 17 726 000, by issuing 7 128 000 new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.

Pursuant to the resolution of the General Meeting from the 19th of April 2008 the capital was increased from BGN 17 726 000 to BGN 18 431 540 through an in-kind contribution.

Pursuant to the resolution of the General Meeting from the 21st of June 2009 the capital was increased from BGN 18 431 540 to BGN 24 435 022, by issuing 6 003 482 new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.

Pursuant to the resolution of the General Meeting from the 15th of November 2010 the capital was increased from BGN 24 435 022 to BGN 31 795 022, by issuing 7 360 000 new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.

Pursuant to the resolution of the General Meeting from the 11th of April 2011 the capital was increased from BGN 31 795 022 to BGN 32 000 000, by issuing 204 978 new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.

Pursuant to the resolution of the General Meeting from the 26th of August 2014 the capital was increased from BGN 32 000 000 to BGN 43 500 000, by issuing 11 500 000 (eleven million five hundred thousand) new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.

Pursuant to the resolution of the General Meeting from the 20th of April 2015 the capital was increased from BGN 43 500 000 to BGN 49 600 000, by issuing 6 100 000 (six million one hundred thousand) new ordinary dematerialized shares with a nominal value of BGN 1 (one). The capital increase was carried out through the capitalization of profits pursuant to Art. 197 of the Commercial Code.

On the 01st of December 2014 the General Meeting of Shareholders adopted a decision Tchaikapharma High Quality Medicines Inc. to become a public company under Art. 110, para. 1, item 2 of the Law on the Public Offering of Securities. In connection with this resolution the Board of Directors has adopted a decision to register the share issue of the Company in the FSC and the BSE.

The Prospectus for the Public Offering of Securities, part of which this Securities Offerings Document is, was approved by the Financial Supervision Commission with Decision № 304 - ПД from the 21st of April 2015.

3. THE SUPPLEMENT TO THE SECURITIES OFFERING DOCUMENT IS TO UPDATE SECTION:

V. TERMS AND CONDITIONS OF THE OFFERING 1. Information about the public offering, a) Terms and Conditions

THE CONTENT OF THE SECTION WILL APPEAR AS FOLLOWS:

49 600 000 ordinary shares with a nominal value of BGN 1 (one) each will be registered for trade on the BSE.

The starting date of the public offering is the date, determined pursuant to the decision of the BSE-Sofia Board of Directors, after approval of the Prospectus and following the application submitted by the Issuer (Art. 31, para. 8, ch. II of the "Rules for Admission to Trading" from the Rules of Procedure of the Bulgarian Stock Exchange Sofia).

After registering the shares for stock trading, the buying and selling of shares will be carried out under Section IV. Information on the securities to be offered / admitted to trading.

Investors and shareholders interested in buying and selling the shares of High Quality Medicines Tchaikapharma Inc. can turn to a licensed investment intermediary - member of the BSE.

TCHAIKAPHARMA HIGH QUALITY MEDICINES INC

INVESTORS CAN GET ACQUAINTED WITH THE ORIGINAL PROSPECTUS AND THE SUPPLEMENT TO THE PROSPECTUS WITH THE DOCUMENTS, TO WHICH THEY REFER, AS WELL AS TO OBTAIN FURTHER INFORMATION ON THE PROSPECTUS AND THE SUPPLEMENT TO THE PROSPECTUS IN THE OFFICE OF TCHAIKAPHARMA HIGH QUALITY MEDICINES INC:

Sofia, 1172
District Izgrev, No1 G.M.Dimitrov Blvd.
as well as on the website:
www.tchaikapharma.com

The Supplement to the Securities Document was drafted by:

Biser Georgiev [signature]

Dimitar Stoyanov [signature]

Biser Ivanov [signature]

The undersigned, as a person representing the Company, with his signature declares that the The Supplement to the Securities Document meets the requirements of the law.

Biser Georgiev
[signature]

CEO
of Tchaikapharma High Quality Medicines Inc.